Key Takeaways GEHC inks exclusive deal with Lantheus to commercialize PYLARIFY in Japan.GEHC leverages Nihon Medi-Physics assets to fast-track PSMA agent launch.GEHC targets Japan's large prostate cancer market with PYLARIFY rollout.GE HealthCare (GEHC) recently announced that it has signed an exclusive license agreement with medical imaging agents and products manufacturer, Lantheus Holdings, gaining access to the development of the latter’s PSMA-targeted PET imaging agent, piflufolastat F18.Per the terms ...